Mather Group LLC. Raises Stock Position in Humana Inc. (NYSE:HUM)

Mather Group LLC. boosted its position in shares of Humana Inc. (NYSE:HUM) by 21.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 236 shares of the insurance provider’s stock after buying an additional 41 shares during the quarter. Mather Group LLC.’s holdings in Humana were worth $60,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tempus Wealth Planning LLC grew its position in Humana by 9.8% during the fourth quarter. Tempus Wealth Planning LLC now owns 878 shares of the insurance provider’s stock valued at $223,000 after buying an additional 78 shares during the period. Columbus Macro LLC acquired a new stake in Humana during the fourth quarter valued at $223,000. Dupree Financial Group LLC acquired a new stake in Humana during the fourth quarter valued at $3,004,000. abrdn plc grew its position in Humana by 15.2% during the fourth quarter. abrdn plc now owns 125,860 shares of the insurance provider’s stock valued at $31,941,000 after buying an additional 16,612 shares during the period. Finally, Bluesphere Advisors LLC acquired a new stake in Humana during the fourth quarter valued at $396,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

Humana stock opened at $274.06 on Friday. The company’s 50 day simple moving average is $274.66 and its 200-day simple moving average is $299.52. The company has a market capitalization of $33.00 billion, a price-to-earnings ratio of 24.27, a price-to-earnings-growth ratio of 2.21 and a beta of 0.56. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Analyst Upgrades and Downgrades

Several research firms recently commented on HUM. TD Cowen raised their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Morgan Stanley lifted their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Wells Fargo & Company dropped their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $297.68.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.29% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.